Endo Axiom is focused on prevention of autoimmune diseases and improving the quality of life of diabetics.
We develop biotechnology platforms for the oral delivery of drug and biologics and take these to clinical validation.
Develop nanotechnology platforms to solve pharmaceutical’s impossible challenges:
oral insulin without hypoglycaemia and immune modulation for the prevention of type 1 diabetes without immune suppression.
EXPERIENCED & INNOVATIVE TEAM
Our management team and board represents some of Australia’s most successful executives including the CEO of one of Australia’s pre-eminent biotechnology incubator, CIO of a global investment fund and a leading scientific expert and co-inventor our technology program. Our scientific advisory board is composed of biotechnology, pharmaceutical and clinical pharmacology experts.